SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-004570
Filing Date
2024-04-02
Accepted
2024-04-02 06:01:03
Documents
16
Period of Report
2024-04-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrxp-20240401x8k.htm   iXBRL 8-K 43457
2 EX-99.1 nrxp-20240401xex99d1.htm EX-99.1 60465
3 GRAPHIC nrxp-20240401xex99d1002.jpg GRAPHIC 3553
  Complete submission text file 0001558370-24-004570.txt   284002

Data Files

Seq Description Document Type Size
4 EX-101.SCH nrxp-20240401.xsd EX-101.SCH 4487
5 EX-101.DEF nrxp-20240401_def.xml EX-101.DEF 14194
6 EX-101.LAB nrxp-20240401_lab.xml EX-101.LAB 20668
7 EX-101.PRE nrxp-20240401_pre.xml EX-101.PRE 15408
19 EXTRACTED XBRL INSTANCE DOCUMENT nrxp-20240401x8k_htm.xml XML 7198
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 24812087
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)